Ovarian Cancer Clinical Trials in Baltimore

Showing 41-60 of 216 trials

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

NCT05360680

This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A\*0201 positive patients with WT1 positive recurrent/metastatic solid tumors who have failed conventional therapies.

Colorectal CancerGastric CancerPancreatic Cancer+1 more

Cue Biopharma42 participantsStarted Jun 2022

Phoenix, Arizona, United States • Los Angeles, California, United States • Palo Alto, California, United States +12 more locations

RECRUITING< 1 mile

EXoPERT EMERALD Clinical Study

NCT07186296

Invitro diagnostic test for multiple cancer diagnosis for patients with early-stage cancers by analyzing surface-enhanced Ramen spectroscopy (SERS) profiles of extracellular vesicles (EV) using artificial intelligence.

Breast CancerColon CancerPancreatic Cancer+2 more

EXoPERT1,400 participantsStarted May 2025

Long Beach, California, United States • Los Angeles, California, United States • Honolulu, Hawaii, United States +6 more locations

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

EXoPERT EMERALD Clinical Study

Ovarian Cancer Trials in Other Cities

Nirogacestat in Ovarian Granulosa Cell Tumors

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Diet, Hepcidin, and Chemotherapy RDI

CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Study of AVZO-021 in Patients With Advanced Solid Tumors

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

A Study of XMT-1660 in Participants With Solid Tumors

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Other Conditions in Baltimore